Symmetry Investments US LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Symmetry Investments US LLC
CRD #317755
SEC #801-128668
CIK #0001861029, 0002004843, 0002111130, 0002055506, 0001691919
AUM 16.83 B (2026-03-31)
Employees 10 (90% Investors, 0% Brokers)
Fees
Minimum
Phone212-381-4000
Address510 Madison Avenue
New York, NY 10022
Source [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn]
Total AUM ($B)
2016128402010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Fees and Compensation
Symmetry Funds. Symmetry US receives compensation indirectly from the Symmetry Funds.
For its management services, the Delegating Manager receives compensation, including
management fees, business and technology services fees and performance fees, from the
Symmetry Funds. The Delegating Manager then compensates Symmetry US for its investment
advisory services pursuant to our sub-advisory arrangement with Symmetry Investments (Hong
Kong) Limited (“SIHKL”).
Separately Managed Accounts. Separately managed account fees are negotiated on a client-by-
client basis and are determined based upon a number of factors including, but not limited to, the
amount and type of advice provided, the size of the asset base, the complexity of the portfolio
and the resources that we anticipate dedicating to the account. Depending on the agreement with
the relevant Client, we can charge management fees that are calculated on the value of the assets
in the SMA, including assets that are financed with leverage or margin, as well as an incentive or
performance fee or allocation (which entitles us to additional compensation based on the increase
in value of those Clients’ accounts or other metrics that we agree to with those Clients). Where
we serve as a sub-adviser to an SMA, our compensation is received subject to the sub-advisory
arrangement with the master adviser (e.g., the Delegating Manager).
Timing. Management fees can be assessed against or deducted from Client accounts on a
periodic basis (e.g., monthly in arrears), but billing matters are individually negotiated and
modified under each sub-advisory arrangement.
Modification. Advisory and other fees generally may be modified in accordance with the terms
of the relevant investment management agreements.

Other Types of Fees or Expenses

Each Client bears its own expenses, including but not limited to:

   •   pass-through expenses including certain investment talent and acquisition costs and trade
       facilitation costs;
   •   investment expenses (e.g., brokerage commissions, expenses relating to short sales,
       clearing and settlement charges, custodial and depositary fees, bank service fees and
       interest expenses);
   •   investment-related travel expenses;
   •   professional fees relating to investments;
   •   fees and expenses relating to software tools, programs or other technology;
   •   research and market data;
   •   administrative expenses;
   •   legal expenses;
   •   external accounting and valuation expenses;
   •   audit and tax preparation expenses;
   •   the costs of any ERISA fidelity bond;
   •   fees of the directors of the Client’s general partners;

   •   costs relating to directors’ and officers’ liability insurance;
   •   costs of printing and mailing reports and notices;
   •   taxes;
   •   corporate licensing;
   •   regulatory expenses;
   •   expenses related to complying with the legal, compliance, regulatory, collateral and
       reporting obligations of, and preparing and making, regulatory and compliance filings
       associated with the respective Client’s investment activities;
   •   listing fees;
   •   organizational expenses;
   •   expenses incurred in connection with the offering and sale of the interests issued by the
       Symmetry Funds and other similar expenses related to the Symmetry Funds;
   •   indemnification expenses; and
   •   extraordinary expenses.

We do not accept, and none of our supervised persons accepts, compensation for the sale of
securities or other investment products.

SMA expense charges and reimbursement arrangements are reflected in the relevant investment
management agreement.

Symmetry US Revenues

As indicated above, Symmetry US acts only as a sub-adviser. As a sub-adviser, Symmetry US
does not have any direct advisory relationships with the Symmetry Funds or with the SMA.

Symmetry US receives its compensation from the Delegating Manager. The amount of
compensation that the Adviser receives is not fixed, and is based on a number of factors,
including Symmetry US’ infrastructure and other costs and expenses and the effect of the
contributions of Symmetry US’ personnel. In some cases, Symmetry US will receive some of its
compensation directly from an affiliate of the SMA client.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7: Types of Clients

Our Clients are:

    •   the Symmetry Funds, described in Item 4 above, which are generally open to investment
        from institutional investors including, without limitation, investment managers, pension
        plans, sovereign wealth and endowments, family offices, and also other sophisticated
        investors which may include high net-worth individuals; and
    •   the SMAs, described in Item 4 above. As of the date of this Brochure, we only sub-
        advise one private fund SMA.
Sector Form 13F Holdings Value ($B)
Apple Inc 0.0
Nvidia Corp 0.0
Cisco Systems Inc 0.0
Amazon Com Inc 0.0
Tempus AI Inc 0.0
Tesla Motors Inc 0.0
Microsoft Corp 0.0
 
 
 
 
Holdings by Sector ($B)
3.02.41.81.20.60.02021202320252027
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 3 16.8
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 16.8
By Discretionary
Discretionary 3 16.8
Non-Discretionary 0 0.0
Total 3 16.8
By Non-United States Persons
Non-United States Persons 16.8
United States Persons 0.0
Total 3 16.8
EDGAR Form CIK 2011 - 2026
13F-HR [0001691919]
3 [0001861029]
4 [0001861029]
13F-HR [0002004843]
13F-NT [0002055506]
D [0002111130]
Firm Profile (Form ADV)
ServesInstitutional
LEI549300POXWQLZSEOUF89
Form 3/4/5 Subject 2011 - 2026
PMV Pharmaceuticals Inc
Simons James H
Euclidean Capital LLC
Symmetry Group Ltd
Greenland FP LLC
Greenland NFP LLC
Greenland NFP B Ltd
Chhabra Ashvin
Greenland A LLC
Simons Marilyn
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-14 Sell 4,699 $34.11 160,283
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-14 Sell 1,260 $34.11 42,979
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-14 Sell 24,726 $34.11 843,404
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-14 Sell 7,141 $34.11 243,580
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-14 Sell 6,593 $34.11 224,887
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-11 Sell 3,262 $33.80 110,256
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-11 Sell 621 $33.80 20,990
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-11 Sell 12,237 $33.80 413,611
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-11 Sell 3,533 $33.80 119,415
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-11 Sell 2,324 $33.80 78,551
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-10 Sell 2,183 $32.68 71,340
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-10 Sell 585 $32.68 19,118
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-10 Sell 3,063 $32.68 100,099
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-10 Sell 3,317 $32.68 108,400
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-10 Sell 11,485 $32.68 375,330
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-09 Sell 4,192 $33.64 141,019
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-09 Sell 22,070 $33.64 742,435
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-09 Sell 6,372 $33.64 214,354
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-09 Sell 5,883 $33.64 197,904
PMV Pharmaceuticals Inc PMVP
Common Stock
2021-06-09 Sell 1,121 $33.64 37,710
showing 20 of 30 most recent transactions
Comparable Firms State AUM
Penserra Capital Management LLC
CA 17.50 B
Limekiln Real Estate Investment Management LP
NY 17.50 B
Life Cycle Investment Partners Limited
17.30 B
Bosera Asset Management International Co Limited
17.26 B
Keystate Advisory LLC
NV 16.59 B
Aristotle Investment Services LLC
CA 16.50 B
Valley View Consulting LLC
16.40 B
Venerable Investment Advisers LLC
PA 16.27 B
Blue Owl Technology Credit Advisors LLC
NY 16.10 B
FS/KKR Advisor LLC
PA 16.10 B
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com